Lung Ultrasound in Detection of Extravascular Lung Water in Septic Patients.
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT03676699 |
|
Recruitment Status :
Completed
First Posted : September 19, 2018
Last Update Posted : September 19, 2018
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
| Condition or disease | Intervention/treatment |
|---|---|
| Ultrasound Therapy; Complications | Diagnostic Test: Ultrasound chest |
| Study Type : | Observational [Patient Registry] |
| Actual Enrollment : | 30 participants |
| Observational Model: | Cohort |
| Time Perspective: | Prospective |
| Target Follow-Up Duration: | 1 Day |
| Official Title: | Lung Ultrasound as an Evolving Tool in Detection of Extravascular Lung Water in Septic Cancer Patients. |
| Actual Study Start Date : | March 30, 2018 |
| Actual Primary Completion Date : | August 30, 2018 |
| Actual Study Completion Date : | August 30, 2018 |
- Diagnostic Test: Ultrasound chest
Ultrasound detection of extravascular lung water
- Detection of B-lines [ Time Frame: 12 hours follow up ]The number of B lines was scanned and a quadrant was considered to be positive when 3 or more B-Lines were recorded. A patient was defined to have positive B-lines (when 3 or more B-Lines are recorded in 3 or more quadrants).
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 18 Years to 65 Years (Adult, Older Adult) |
| Sexes Eligible for Study: | All |
| Sampling Method: | Non-Probability Sample |
Inclusion Criteria:
- Patients aged between (18 - 65) years.
- Diagnosed with severe sepsis or septic shock according to the third international consensus definition (sepsis-3).
- All of them underwent major abdominal oncologic surgeries.
Exclusion Criteria:
- ASA III and IV patients.
- Patients with BMI>35.
- Patients who suffered from chronic lung disease.
- History of cardiac or renal problems.
- Patients with lung cancer or pulmonary metastases.
- Patients with inserted chest tubes.
- Presence of subcutaneous emphysema.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03676699
| Egypt | |
| Department of Anesthesia and Pain medicine.National Cancer Institute | |
| Cairo, Egypt, 11796 | |
| Principal Investigator: | Ehab H Shaker, MD | National Cancer Institute- Cairo University |
| Responsible Party: | Ehab Hanafy Shaker, lecturer of anesthesia ,critical care and pain medicine, National Cancer Institute, Egypt |
| ClinicalTrials.gov Identifier: | NCT03676699 |
| Other Study ID Numbers: |
Ehab-Walaa.Ultrasound |
| First Posted: | September 19, 2018 Key Record Dates |
| Last Update Posted: | September 19, 2018 |
| Last Verified: | September 2018 |
| Individual Participant Data (IPD) Sharing Statement: | |
| Plan to Share IPD: | Undecided |
| Plan Description: | after finishing the submission ,we planned to share the results and conclusion for further benefits. |
| Studies a U.S. FDA-regulated Drug Product: | No |
| Studies a U.S. FDA-regulated Device Product: | No |
|
Extravascular lung water, inferior vena cava collapsibility |

